Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Affiliations

• ¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
• ² Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), University of Seville, Seville, Spain.
• ³ Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
• ⁴ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
• ⁵ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
• ⁶ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
• ⁷ Centre for Trials Research, Cardiff University, Cardiff, UK.
• ⁸ Guy's and St. Thomas Hospital, London, UK.
• ⁹ HOVON Foundation, Rotterdam, The Netherlands.
• ¹⁰ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ¹¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. [email protected].
• ¹² Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. [email protected].
• ¹³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. [email protected].